Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.
HPB (Oxford). 2022 Oct;24(10):1748-1756. doi: 10.1016/j.hpb.2022.05.1341. Epub 2022 May 28.
Intrahepatic Cholangiocarcinoma (iCCA) is an aggressive cancer with diverse mutational profiles. An important molecular subtype is fibroblast growth factor receptor 2 (FGFR2) fusion. The effect of FGFR2 fusions on prognosis is unknown. Our aim was to assess the outcomes in resected CCA patients in relation to FGFR2 status.
Surgically treated CCA patients from a single institution were retrospectively reviewed between 2008 and 2014. FGFR rearrangements were detected by fluorescence in situ hybridization (FISH). Data included patient demographics, tumor pathology, disease-free survival (DFS) and overall survival (OS).
Ninety-five patients underwent surgical resection for iCCA. Twelve (13%) of these were found to have FGFR2 fusion, none of which were treated with FGFR targeted therapy. Patients with FGFR2 fusions were found to have a longer 5-year (83 vs. 32%, p = 0.01) and 10-year (46 vs. 22%, p = 0.04) OS. Five and 10-year DFS was also increased (68 vs. 33% p = 0.04) and (68 vs. 25 %, p = 0.02,). FGFR2 fusion status was the strongest independent factor associated with improved OS (HR 0.23, 0.09-0.62, p=0.003) and DFS (HR 0.18, 0.05-0.67, p=0.01).
Patients with CCA FGFR2 fusion have improved OS and DFS following surgical resection.
肝内胆管癌（iCCA）是一种具有多种突变特征的侵袭性癌症。一个重要的分子亚型是成纤维细胞生长因子受体 2（FGFR2）融合。FGFR2 融合对预后的影响尚不清楚。我们的目的是评估与 FGFR2 状态相关的接受手术治疗的 CCA 患者的结局。
对 2008 年至 2014 年间在单一机构接受手术治疗的 CCA 患者进行回顾性研究。通过荧光原位杂交（FISH）检测 FGFR 重排。数据包括患者的人口统计学、肿瘤病理学、无病生存期（DFS）和总生存期（OS）。
95 例患者接受手术切除 iCCA。其中 12 例（13%）发现 FGFR2 融合，均未接受 FGFR 靶向治疗。FGFR2 融合患者的 5 年（83%比 32%，p=0.01）和 10 年 OS（46%比 22%，p=0.04）均较长。5 年和 10 年 DFS 也有所提高（68%比 33%，p=0.04）和（68%比 25%，p=0.02）。FGFR2 融合状态是与改善 OS（HR 0.23，0.09-0.62，p=0.003）和 DFS（HR 0.18，0.05-0.67，p=0.01）最显著的独立相关因素。
接受手术切除的 CCA FGFR2 融合患者的 OS 和 DFS 得到改善。
